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Significance 
 
• According to the Center for Disease Control and Prevention, epilepsy 
affects 2.2 million Americans and 65 million people worldwide 
• Epileptic seizures can severely limit school achievements, employment 
prospects, and participation in other life experiences. 
• Traumatic brain injury is one of the major risk factors causing 
epileptogenesis; the development of epilepsy.  
 
Background Information 
 
• Insulin-like growth factor 1 (IGF-1) levels are 
elevated in the brain following head injury 
• Earlier research suggests that IGF-1 has pro-
epileptogenic effects 
• It is known that the binding of IGF-1 to IGF-1 
receptors leads to the activation of MAPK and 
PI3K signaling cascades, but it is not clear 
whether IGF-1 activates mTOR, or operates 
in parallel to the PI3K-Akt-mTOR cascade 
through activation of MAPK 
 
 Aims and Approach 
 
Aim 1: What are the downstream effectors of IGF-1 in an organotypic 
hippocampal culture model of posttraumatic epileptogenesis, and is 
there cross-talk with pro-epileptogenic PI3K-Akt-mTOR signaling? 
  In order to answer these questions, Western Blot is used to 
measure levels of phosphorylation of  Akt, MAPK, and S6 (a 
marker of mTOR activation), during early post injury period and 
latent period with and without IGF-1 in the culture medium. 
  
Aim 2: Determine the timeline of the signaling cascade. 
  Measuring the presence of phosphorylated Akt, MAPK, and S6 
both with and without IGF-1 will lead to conclusions on the effects 
of IGF-1 on the different steps in the cascade. These conclusions 
will allow us to determine the sequence in which the pathway 
operates.  
 
  
Results 
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Figure 1: Row 1 represents Akt, 
rows 2 and 3 represent MAPK, and 
row 4 represents S6. Lane 1 shows 
proteins at DIV0, lane 2 shows 
DIV1, and so on up to DIV6 in lane 
7. The left film has a exposure time 
of 20 seconds, and the right has an 
exposure time of 1 minute. These 
films show phosphorylated proteins 
in the sample. 
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Figure 2: This image uses the same samples, 
but measures total Akt, S6, and MAPK rather 
than phosphorylated protein. Both are used so 
that a ratio can be made between 
phosphorylated and total protein in order to 
determine a relative phosphorylation. 
 In these films, it is clear that protein phosphorylation varies over time, with 
the greatest amounts of pS6 and pAkt occurring during DIV1 and DIV2. 
Although this does not prove any specific conclusion, it does show that 
during recovery, more activity occurs during the first and second day, and 
lessens as the days increase. These results give a basis for future 
experiments; samples should be tested at DIV3. This is when the circuits 
that were affected by the injury start to rebuild 
Figure 3: The image on the left shows 
the slice from the first run of an 
experiment that was performed, while 
the figure on the right shows the 
repeated experiment. The hole in the 
left slice is damage, which led to 
negative results in this specific 
experiment. This shows the importance 
of the hippocampus slice. 
Figure 4: The film has an exposure time of 5 
minutes. Lanes 1-3 were treated with +IGF-1 
while lanes 4-6 were starved of IGF-1 at DIV3. 
The results of this experiment were positive for 
all three proteins. On this film, the +IGF-1 
samples showed more protein phosphorylation 
than the –IGF-1 samples.  
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Analysis 
 A program called Fiji ImageJ was used to 
collect the data for this experiment. This 
program gave values to each band based on 
band brightness, and these numerical values 
can be used to interpret the data and make 
relative ratios of phosphorylated protein to total 
protein. 
 Over 30 experiments have been done, some being repeat 
experiments. So far, we have concluded that +IGF gives 
approximately 50% increase in phosphorylation of Akt and pS6. 
This is our only consistent conclusion to date, but it is clear that 
IGF-1 does have a positive effect on protein phosphorylation. 
MAPK also shows evidence of playing a role in the signaling 
cascade, but it is not clear how it effects the pathway.The question 
now is how exactly does IGF-1 respond to injury and what is the 
timeline of the cascade? This experiment is still in the workings, 
but once all data is collected and analyzed it will be possible to 
answer our first aim, make strides toward the second, and to 
continue on to accomplish the long term aim in the future.  
Conclusion 
Figure 5: These 
graphs show relative 
ratios of 
phosphorylated 
protein/total protein. 
From this data, we 
can conclude MAPK 
is the potential 
signaling effector in 
the pathway. This 
experiment does not 
finalize this fact, but 
a follow up study 
would be to inhibit 
MAPK to see how 
this affects 
epileptogenesis 
